Introduction
The inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, affect $1.4 million people in the USA (1) . Non-steroidal anti-inflammatory drugs (NSAIDs) are reported to trigger and exacerbate these diseases (2) , although these results are controversial (3) . Because all commonly used NSAIDs exert their major pharmacological effects by inhibiting cyclooxygenase (COX) enzyme activity, COX activity appears to retard colon inflammation in these diseases. NSAIDs, which inhibit both COX-1 and COX-2, and COX-2 inhibitors, which preferentially inhibit COX-2, also exacerbate dextran sulfate sodium (DSS)-induced experimental colitis in rats and mice (4, 5) . Although there are also contradictory reports for pharmacological studies in rodents (6) , genetic studies using Cox-2-knockout mice clearly demonstrate that endogenous COX-2 activity plays a beneficial role in DSS-induced colitis; global COX-2 deletion exacerbates DSSinduced colitis in mice (4) .
Patients with IBDs are at greater risk for colorectal cancer (7, 8) . Although inhibition of COX-2 activity is clearly beneficial in reducing colon cancer both in hereditary Familial Adenomatous Polyposis and in spontaneously occurring colon cancer, the role of COXs and prostaglandins in the development of colorectal cancer in IBD patients is controversial (9, 10) . We have recently demonstrated that, despite the clear protective role for COX-2 in DSS-induced colitis (4, 5) , global deletion of COX-2 does not reduce murine susceptibility to azoxymethane-initiated DSS-promoted colorectal cancer (11) .
The COXs play critical roles in prostanoid biosynthesis. COX enzymes convert free arachidonic acid, released from membrane phospholipids by phopholipase, to prostaglandin H 2 . prostaglandin H 2 is the precursor for all prostanoids: the prostaglandins, thromboxanes and prostacyclins. Expression patterns of the two COX isoforms, COX-1 and COX-2, differ substantially; COX-1 is constitutively expressed in most tissues, whereas COX-2 expression is induced in different tissues in response to a wide range of physiological inducers (12) . COX-2 induction has been demonstrated in endothelial cells, epithelial cells, neurons, macrophages, osteoblasts, chondrocytes and other cell types, in response to distinct stimuli (13) . Synthesis of alternative prostanoids in different cells and tissues is determined by the presence of alternative enzymes that convert prostaglandin H 2 to alternative products.
Oral administration of DSS polymers to rodents is one of the most widely used models of ulcerative colitis (14) . DSS dissolved in drinking water is toxic to the epithelial lining of the rodent colon, resulting in acute colitis that is characterized by weight loss, colon ulceration and bloody diarrhea. In the DSS model in rats, COX-2 production is observed in smooth muscle, blood vessels, infiltrating cells in the submucosa and macrophages (5) . The number of lamina propria mononuclear cells expressing COX-2 increases during DSS-induced inflammation in the mouse intestine (15) . Immunofluorescent studies in mice also suggest epithelial cell COX-2 elevation in DSS-treated mice (16) .
The studies described above suggest that COX-2 is expressed in a number of cell types during the development of DSS-induced colitis. However, we do not know in which cell type(s) COX-2 expression is important for reduction of colitis symptoms. Only the effects of total systemic blockade of COX-2 function can be determined with NSAID or COX-2 inhibitors treatment (17, 18) . Similarly, only the effects of total systemic elimination of COX-2 expression can be determined in mice with a global Cox-2 gene deletion (4) . To identify the cell type(s) in the colon in which COX-2 suppression exacerbates DSS-induced colitis, we used Cox-2 flox/flox mice, in which Cox-2 exons 4 and 5 are flanked by loxP sites (19) . In this study, we crossed Cox-2 flox/flox mice with mice-expressing Cre recombinase in myeloid cells, endothelial cells and intestinal epithelial cells and examined the effect of cell type-specific Cox-2 deletion on DSS-induced colitis.
Materials and methods

Mice
Mice carrying a knock-in allele of the firefly luciferase-coding region in the Cox-2 gene (Cox-2 luc mice) and mice in which Cox-2 exons 4 and 5 are flanked by loxP sites for conditional knockout (Cox-2 flox/flox mice) were generated as described previously (19, 20) . LysMCre knock-in mice (B6.129P2-Lyzs tm1(cre)lfo Mouse models of colitis Twelve-week-old mice received 2.5% DSS (molecular weight, 36 000-50 000; MP Biomedicals, Solon, OH) in their drinking water for 8 days prior to killing. Body weight was measured each day during the DSS treatment; weight change was calculated as the percentage change compared with the weight prior to DSS treatment. Stool consistency was monitored and occult blood in the stool was tested daily using Hemoccult cards (Beckman Coulter Inc., Fullerton, CA). To assess the extent of colitis, body weight, stool consistency and Hemoccult results were scored as follows (22) . Weight loss: 0, no weight loss; 1, 1-5%; 2, 5-10%; 3, 10-20% and 4, .20%. Stool consistency: 0, well-formed pellets; 2, pasty and semiformed stools that did not stick to anus and 4, liquid stools that did stick to the anus. Hemoccult bleeding measurement: 0, no blood in hemoccult; 2, positive hemoccult and 4, gross bleeding. Scores for each category are added for each mouse and divided by 3 (from 0.0 for healthy to 4.0 for maximal activity of colitis) to obtain the final clinical score. After DSS treatment, the colons were isolated, rinsed with phosphate-buffered saline, filled with 4% paraformaldehyde and opened longitudinally for histological examination.
Detection of luciferase activity
For ex vivo colon imaging, mice were anesthetized by intraperitoneal administration of a ketamine (80 mg/kg; Phoenix Pharmaceutical, St Joseph, MO) and xylazine (4 mg/kg; Phoenix Pharmaceutical) mixture. Anesthetized mice were injected intraperitoneally with D-luciferin (125 mg/kg; Caliper Life Sciences, Hopkinton, MA) and placed in the light-tight box of the IVIS 100 imaging system (Caliper Life Sciences). Whole body 1 min images were acquired repeatedly. After the photon number during the 1 min scans reached a maximum, the mice were killed and the colons were rapidly excised. Isolated colons were placed on culture dishes and imaged with the IVIS system. Collected photon number and images were analyzed using LIVING IMAGE software (Caliper Life Sciences).
Histology and immunohistochemistry
Mouse colon tissues fixed in 4% paraformaldehyde were paraffin-embedded and sectioned at 4 lm thickness. The sections were either stained with hematoxylin and eosin or processed for immunostaining.
The crypt damage was scored as follows for hematoxylin-and eosin-stained sections ( Figure 3C ): grade 0 5 intact crypt; 1 5 loss of the basal one-third of the crypt; 2 5 loss of the basal two-third of the crypt; 3 5 entire loss of crypt and 4 5 loss of crypt and surface epithelium (22) .
COX-2 was detected with polyclonal anti-COX-2 antibody (Thermo Scientific). To detect macrophages, rat monoclonal antibody for F4/80 (Serotec, Oxford, UK) was used. To detect endothelial cells, rat anti-mouse CD34 (BD Biosciences, San Diego, CA) was used. Staining signals were visualized by using appropriate Alexa Fluor 594-or Alexa Fluor 488-conjugated secondary antibodies (Molecular Probes, Eugene, OR). To detect epithelial cells, monoclonal antibody for pan-keratin conjugated with Alexa Fluor 488 (Cell Signaling Technology, Danvers, MA) was used.
Isolation of peritoneal macrophage
Mice were injected intraperitoneally with 3 ml of 3% thioglycolate medium (Sigma). After 3 days, macrophages were obtained by lavage of the peritoneal cavity with phosphate-buffered saline. Cells were washed, resuspended in Dulbecco's modified Eagle's medium containing 10% serum and plated in this same medium. For COX-2 induction, cells were treated with lipopolysaccharide (LPS, 200 ng/ml) for 6 h. Culture supernatants were collected for prostaglandin E 2 (PGE 2 ) analysis; cells were lysed for western blotting.
Genomic Southern hybridization
Genomic Southern hybridization for the detection of Cox-2 flox and recombined Cox-2 del alleles was performed as described previously (19) .
Western immunoblotting
Cell lysates were separated in 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes (100 lg total protein per lane). COX-2 was detected with polyclonal anti-murine COX-2 antibody (Cayman Chemical, Ann Arbor, MI); Glyceraldehyde-3-phosphate dehydrogenase was detected with polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology, Santa Cruz, CA). The ECL detection system (Thermo Scientific, Rockford, IL) was used to visualize the signals on X-ray film.
Prostaglandin analysis
Media from peritoneal macrophage cultures were collected and assayed for PGE 2 using an enzyme immunoassay system (GE Healthcare, Piscataway, NJ).
In situ cell proliferation assay Mice were injected intraperitoneally with 100 mg/kg of either bromodeoxyuridine (BrdU; Sigma) or 5-ethynyl-2#-deoxyuridine (EdU; Molecular Probes) 2 h before killing. Tissue samples were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned. Incorporated BrdU and EdU were visualized with the BrdU In-Situ Detection Kit (BD Biosciences) or the Click-iT EdU imaging kit (Molecular Probes), respectively.
Apoptosis assay
Apoptosis was determined on paraffin sections with the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) method, using the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore, Temecula, CA).
Isolation of colon epithelial cells
Colon epithelial cells were dissociated by ethylenediaminetetraacetic acid treatment (23) . Colons were isolated, opened and washed initially with phosphate-buffered saline. Tissue samples were then washed three times with Hank's buffered saline solution with 25 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid and 1% fetal bovine serum and then stirred for 15 min in Hank's buffered saline solution with 50 mM ethylenediaminetetraacetic acid. Tissues were allowed to settle; dissociated cells in the supernatant were collected as the epithelial cell fraction. Settled tissue fragments were subjected to two more cycles of stirring and collection of epithelial cells. All procedures were performed at room temperature.
Isolation of endothelial cells
Livers were removed, minced and incubated in 0.1% collagenase (Invitrogen, Carlsbad, CA) and 2.5 U/ml dispase (Invitrogen). Dissociated cells were passed through a Cell Strainer (BD Biosciences), washed and incubated with anti-LSEC microbeads (MACS system; Miltenyi Biotec Inc., Auburn, CA). Flow through and bound fractions were collected with the aid of a MiniMACS separation unit (Miltenyi Biotec Inc.). Genomic DNA was isolated from the flow through and antibody-bound cell fractions and analyzed by polymerase chain reaction for Cox-2 flox and Cox-2 del alleles (19).
Results
COX-2 is expressed in multiple cell types in murine DSS-induced colitis
Although COX-2 is normally expressed at low levels in colon tissue, significant elevation of COX-2 protein expression was detected in colons by immunohistochemistry in mice subjected to DSS-induced colitis (16) . We previously generated a Cox-2 luciferase knock-in allele, Cox-2 luc , in which the firefly luciferase reporter enzyme is expressed at the start site of translation of the endogenous Cox-2 gene, to analyze Cox-2 transcriptional activity in the mouse (20) . Consistent with the previous report (24), 3 days of DSS treatment (2.5% in drinking water) created ulcers in the descending colon and rectum of Cox-2 luc/þ heterozygous knock-in mice ( Figure 1A ). These inflamed areas are clearly visualized by ex vivo imaging of Cox-2 promoter-driven luciferase activity ( Figure 1B ). Strong COX-2 immunohistochemical staining has been shown in colonic epithelium and lamina propria cells of mice treated with DSS (16) . To determine the cell types, which express COX-2 in our experiments, double immunohistochemical staining of COX-2 and cell typespecific markers was performed on inflamed colons from wild-type mice treated for 8 days with DSS ( Figure 1C -E). Colon sections were stained for COX-2 along with F4/80, a representative macrophage marker ( Figure 1C ), CD34, an endothelial cell marker ( Figure 1D ) or pan-keratin, an epithelial cell marker ( Figure 1E ). Doubly stained cells were detected for all these marker-positive cells. These costaining experiments demonstrate that COX-2 expression is induced in multiple cell types in the colon, including (but not necessarily limited to) macrophages, endothelial cells and epithelial cells, after DSS administration.
Myeloid cell-specific Cox-2 deletion exacerbates DSS-induced colitis It is clear from studies with DSS-treated Cox-2 knockout mice that eliminating COX-2 function in all cells of the body exacerbates inflammatory colitis (4). However, we cannot determine, by using either conventional knockout mice or pharmacological inhibitors, in which
cell type loss of COX-2 function elicits exaggerated colitis. To identify the cell type(s) in which loss of COX-2 function enhances the colitis response to DSS, mice with a Cox-2 conditional knockout allele (Cox-2 flox ) in which Cox-2 exons 4 and 5 are flanked by loxP sequences (19) were crossed with appropriate Cre-expressing mice and offsprings were treated with DSS.
Because the macrophage is one of the cell types in which COX-2 expression is highly induced in a number of inflammatory conditions, we first crossed Cox-2 flox mice with LysMCre knock-in mice. LysMCre mice express Cre recombinase in myeloid cell lineages, including macrophages (25) . To confirm Cre-mediated recombination of loxP sites, peritoneal macrophages were isolated from Cox-2 flox/flox ;LysM Cre/þ and littermate Cox-2 flox/flox mice and recombination at the Cox-2 flox locus was examined by genomic Southern hybridization ( Figure 2A) . Shift of the Cox-2 band to the lower (8 kb) position indicates nearly complete excision of the loxP-flanked sequence (19) in Cox-2 flox/flox ;LysM Cre/þ macrophages.
COX-2 expression in peritoneal macrophages is highly induced in response to LPS administration; LPS treatment of littermate Cox-2 flox/flox macrophages express substantially elevated COX-2 protein levels ( Figure 2B ). In contrast, COX-2 protein expression in response to LPS is eliminated in Cox-2 flox/flox ;LysM Cre/þ macrophages. Production of PGE 2 following LPS stimulation of macrophages requires COX-2 protein synthesis. However, in Cox-2 flox/flox ;LysM Cre/þ macrophages, PGE 2 accumulation induced by LPS treatment is eliminated ( Figure 2C ). To confirm knockout of the Cox-2 gene in colon macrophages of DSS-treated Cox-2 flox/flox ;LysM Cre/þ mice, sections from the colons of mice receiving DSS for 8 days were costained with anti-COX-2 and anti-F4/80 (macrophage marker) antibodies ( Figure 3D ). Double stained cells are observed in the inflamed colons of Cox-2 flox/flox control mice. In contrast, in the colons of Cox-2 flox/flox ; LysM Cre/þ mice, F4/80:COX-2-positive cells are substantially reduced, indicating successful cell type-specific disruption of the Cox-2 gene.
Low-dose (2.5%) DSS treatment causes significant body weight loss and elevated clinical scores in Cox-2 global knockout mice when compared with wild-type control mice (4) . To determine whether loss of COX-2 expression in myeloid cells contributes substantially to this phenotype, Cox-2 flox/flox ;LysM Cre/þ myeloid Cox-2-knockout mice and Cox-2 flox/flox littermate controls were treated with 2.5% DSS. Compared with littermate control, Cox-2 flox/flox mice without Cox-2 deletion, Cox-2 flox/flox ;LysM Cre/þ mice showed significantly greater Cell type specific Cox-2 deletion in murine colitis loss of weight ( Figure 3A ) and higher clinical scores ( Figure 3B ). The degree of crypt epithelial damage was determined by histological examination ( Figure 3C and D) . At day 8, increased areas of colon show ulceration ( Figure 3C ), and the crypt epithelial damage score is higher ( Figure 3D ) in Cox-2 flox/flox ;LysM Cre/þ colons when compared with Cox-2 flox/flox littermate controls. PGE 2 plays a role in the epithelial cell proliferation associated with recovery from DSS-induced colitis (15) . The exacerbated colitis induced by DSS in Cox-2 flox/flox ;LysM Cre/þ mice could be due to reduced epithelial cell proliferation during the recovery from injury, as a result of reduced macrophage prostaglandin production in these mice. To examine this possibility, Cox-2 flox/flox ;LysM Cre/þ and littermate Cox-2 flox/flox mice treated with DSS were injected with EdU, a thymidine analogue whose incorporation can be measured with a clickchemistry probe (26), 2 h before mice were killed for histological examination. Five days after DSS administration, the number of EdU-labeled proliferating cells is significantly lower in Cox-2 flox/flox ;-LysM Cre/þ mice than in littermate Cox-2 flox/flox mice ( Figure 3E and F). Western blotting of colon lysates of DSS-treated mice with anti-PCNA antibody also demonstrated reduced cell proliferation in colons of DSS-treated Cox-2 flox/flox ;LysM Cre/þ mice when compared with colons from DSS-treated Cox-2 flox/flox littermate mice (data not shown). Similar results were also obtained by Ki67 staining 8 days after DSS administration (data not shown).
We also examined whether Cox-2 deletion in myeloid cells affected colon epithelial cell survival in DSS-treated mice. Three days after DSS administration, the numbers of TUNEL-positive cells are significantly higher in Cox-2 flox/flox ;LysM Cre/þ mice when compared with littermate Cox-2 flox/flox mice ( Figure 3G and H) . This difference in apoptotic cells is not seen at later time points following DSS treatment (data not shown), when a substantial difference is observed in colon epithelial cell proliferation.
Endothelial cell-specific Cox-2 deletion exacerbates murine DSSinduced colitis Immunofluorescent staining demonstrated that endothelial cells also express COX-2 after DSS treatment ( Figure 1D ). To examine the role of endothelial cell COX-2 in DSS-induced colitis, Cox-2 flox/flox mice were crossed with VECadCreERT2 Tg mice. These mice express a tamoxifen-inducible Cre recombinase (CreERT2) transgene under the regulation of the vascular endothelial cadherin (VECad) promoter (21) . CreERT2 was activated by tamoxifen injection in adult animals, to avoid the Cre recombination of Cox-2 flox alleles in cells of the hematopoietic linage (21), including myeloid cells.
Recombination of the Cox-2 flox allele was examined in endothelial cells isolated from livers of tamoxifen-treated Cox-2 flox/flox ;VECadCreERT2
Tg mice and littermate Cox-2 flox/flox mice. Because the numbers of recovered cells were not sufficient for genomic Southern hybridization, recombination was examined by polymerase chain reaction. The Cre-excised product was detected in the endothelial cell-enriched fraction from tamoxifen-treated Cox-2 flox/flox ;VECadCreERT2 Tg mice ( Figure 4A ). To exclude the possibility of recombination of the Cox-2 flox allele in myeloid cells in Cox-2 flox/flox ;VECadCreERT2 Tg mice, peritoneal macrophages were analyzed by genomic Southern hybridization ( Figure 4B ). In contrast to the macrophage from Cox-2 flox/flox ;LysM Cre/þ mice (Figure 2A) , little or no recombination was detected in Cox-2 flox/flox ;VECadCreERT2 Tg macrophage ( Figure   Fig T. Ishikawa et al. 
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Cre/þ mice than in colon sections from littermate Cox-2 flox/flox mice (P , 0.01 by t-test).
Cell type specific Cox-2 deletion in murine colitis 4B). To confirm the cell type specificity of Cox-2 deletion in the colons of DSS-treated Cox-2 flox/flox ;VECadCreERT2 Tg mice, colon sections from mice treated with DSS for 8 days were double stained with anti-COX-2 and either anti-CD34 or anti-F4/80. As expected, blood vessel cells were costained with both COX-2 and CD34 antibodies in the colons of Cox-2 flox/flox littermates. However, CD34-positive endothelial cells are negative for COX-2 in Cox-2 flox/flox ;VECadCreERT2 Tg colon ( Figure 4C ). In contrast, F4/80:COX-2 double-positive macrophages are observed in both Cox-2 flox/flox ;VECadCreERT2 Tg and Cox-2 flox/flox littermate colons, as expected ( Figure 4D ). These staining patterns, like genomic analyses from isolated cells ( Figure 4A and B) , indicate endothelial cell-specific Cox-2 knockout, with normal COX-2 expression in myeloid cells, in Cox-2 flox/flox ;VECadCreERT2 Tg mice. Both body weight loss ( Figure 5A ) and clinical scores ( Figure 5B ) were significantly exacerbated in response to DSS-induced colitis in endothelial cell-specific Cox-2-knockout Cox-2 flox/flox ;VECadCreERT2 Tg mice when compared with littermate Cox-2 flox/flox mice. In addition, histological crypt damage is significantly higher in Cox-2 flox/flox ;VECadCreERT2 Tg mice than in littermate Cox-2 flox/flox mice ( Figure 5C and D) .
To examine the possibility that an endothelial cell-specific Cox-2 knockout, like the myeloid-specific Cox-2 knockout, affects epithelial cell proliferation following DSS insult, Cox-2 flox/flox ;VECadCreERT2
Tg and littermate Cox-2 flox/flox mice were treated with DSS for 5 days and then injected with BrdU 2 h before killing. In DSStreated Cox-2 flox/flox littermate mice, areas with clusters of BrdUpositive epithelial cells are observed ( Figure 5E ). In contrast, similar areas are not observed in colons of DSS-treated Cox-2 flox/flox ;VECadCreERT2
Tg mice, although a small number of BrdU-positive cells are present ( Figure 5E ). Overall, the labeling index through mid to distal colon is significantly lower in Cox-2 flox/flox ;VECadCreERT2 Tg mice when compared with littermate Cox-2 flox/flox mice ( Figure 5F ).
We also examined the number of apoptotic cells at 3 days and 5 days after DSS treatment. In contrast to the results with Cox-2 flox/flox ; LysM Cre/+ mice ( Figure 3H ), no statistically significant difference in TUNEL-positive cells was observed between Cox-2 flox/flox ;VECadCreERT2
Tg mice and littermate Cox-2 flox/flox mice at these two time points ( Figure 5G ). Figure  1E and ref. (16)]. To examine the role of epithelial cell COX-2 in DSS-induced colitis, Cox-2 flox/flox mice were crossed with VillinCre transgenic mice. VillinCre mice express Cre recombinase throughout the entire intestinal epithelium (27) . Recombination of the Cox-2 flox allele in Cox-2 flox/flox ;VillinCre Tg mice was confirmed in epithelial cells dissociated from colon by ethylenediaminetetraacetic acid ( Figure 6A ). In contrast to the results for Cox-2 flox/flox ;LysM Cre/þ mice and Cox-2 flox/flox ;VECadCreERT2 Tg mice, Cox-2 flox/flox ;VillinCre Tg mice and control Cox-2 flox/flox littermates treated with 2.5% DSS displayed the same levels of body weight loss ( Figure 6B ) and clinical scores ( Figure 6C ), indicating that COX-2 expressed in epithelial cells is not involved in development of DSS-induced colitis.
Epithelial cell-specific Cox-2 deletion does not exacerbate murine DSS-induced colitis COX-2 expression is also induced in epithelial cells by DSS [
Discussion
COX-2 levels are elevated in a variety of pathophysiological conditions, including (but not limited to) acute and chronic inflammation, neurodegenerative diseases, cancer, ischemia and pain (28, 29) . The causal role of COXs in general and COX-2 in particular in these conditions is demonstrated by their responses to NSAIDs and COX-2 inhibitors, respectively. The use of mice with a global Cox-2 gene deletion has given researchers an additional investigative tool that permits analysis of the consequences of unequivocal removal of the function of the COX-2 protein, eliminating problems of drug accessibility, pharmacokinetics and off-target effects.
In many-if not most-of the disorders cited above, COX-2 levels are elevated either simultaneously or sequentially in a variety of cell types within the affected tissues. The role of COX-2 and its products produced by distinct cell types-e.g. stromal cells, immune cells, epithelial cells and endothelial cells-in the progression and/or resolution of these conditions cannot be determined either by pharmacological means or by global Cox-2 gene deletion; both cause indiscriminant (with respect to cell type) inhibition/elimination of COX-2, excluding any information on the distinct role(s) of COX-2-dependent prostanoids produced by alternative cell types. To investigate cell-specific roles of COX-2, we created mice carrying the Cox-2 flox allele (19). COX-2 production can be eliminated in specific cell types in Cox-2 flox/flox mice by crossing with mice in which Cre 
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recombinase is expressed from appropriate promoters, and the consequences of cell type-specific COX-2 inactivation can be analyzed. Clinical colitis and its animal model, DSS-induced colitis, are unusual in that pharmacological and genetic data suggest that COX-2 is protective against an inflammatory insult (15,16). COX-2 expression is elevated in DSS-induced colitis in a variety of cell types, including myeloid cells, endothelial cells and epithelial cells. For example, DSS-induced COX-2 elevation in rats is observed in smooth muscle, blood vessels, infiltrating cells in the submucosa and in macrophages (5) . In mice, the number of lamina propria mononuclear cells, epithelial cells and macrophages expressing COX-2 increases during DSS-induced inflammation (15, 16) . In IBD patients, elevated COX-2 expression is also observed in epithelial cells and inflammatory cells (30, 31) , and a relationship between endoscopic activity and the level of COX-2 messenger RNA has been demonstrated (32) . Distinctions in the cell types in which COX-2 elevation is observed during colon inflammation may result from differences in the nature of the model system, the extent of injury, the time of analysis and/or in Cell type specific Cox-2 deletion in murine colitis immunohistochemical procedures. We also found that elevation of COX-2 expression occurs in epithelial cells, endothelial cells and macrophages in response to DSS-induced colitis in mice, leading to our initial choices for targeted Cox-2 deletion studies. Epithelial cells destroyed in the intestinal epithelium following DSS treatment are replaced by proliferation and differentiation of precursor cells. Our results demonstrate that the signals for this proliferative response depend on COX-2 production by myeloid/macrophage cells and by endothelial cells. In contrast, signals for proliferation of epithelial cell precursors in the damaged colon do not depend on COX-2 production in the remaining epithelial cells.
Macrophages play a required role in the epithelial repair process following DSS-induced colon damage (33) . This repair process also requires recognition of commensal microflora by the innate immune system (34) . Compensatory proliferation of epithelial cells after DSSinduced injury, following recognition of microflora, is mediated by bacterially derived endotoxin stimulation of toll-like receptors and is thought to be mediated by toll-like receptor-and MyD88-dependent nuclear factor-kappaB activation (16, (33) (34) (35) . COX-2 expression induced by DSS injury is also dependent on commensal bacteria (33) and the presence of toll-like receptor 4 (16). Greten et al. (36) report that myeloid-specific inhibition of nuclear factor-kappaB activation reduces DSS-induced COX-2 expression. The results presented here also suggest that macrophage COX-2 plays a critical role both in macrophage-dependent protection of epithelial cells from apoptosis following DSS-induced colon damage and in macrophage promoted epithelial cell precursor proliferation to repair the damaged colon.
Exogenous PGE 2 protects against DSS-induced colitis (15) . Global deletion of the EP4 PGE 2 receptor exacerbates DSS-induced colitis (17) also suggesting that PGE 2 protects the epithelium against this inflammatory insult. DSS-induced epithelial injury permits exposure of both epithelial cells of the intestine and macrophages of the lamina propria to commensal bacteria, leading to stimulation of COX-2 production and elevated PGE 2 production (37). Although COX-2 is increased both in colon epithelial cells and in macrophages in response to DSS treatment (Figure 1) , the biological consequences of COX-2 expression/PGE 2 production in macrophages versus epithelial cells has not previously been determined. Our data suggest that DSS-induced COX-2 production in epithelial cells does not play a role in ameliorating intestinal damage. In contrast, macrophage COX-2 induced by the same insult is required both to protect against colitis damage and to enhance recovery.
We find that specific loss of COX-2 expression in endothelial cells also exacerbates DSS-induced colitis. Although several reports suggest endothelial cell involvement in DSS-induced colitis (38) (39) (40) (41) (42) (43) , a role for endothelial cell COX-2 expression has only recently been considered (44, 45) . These reports discuss COX-2 only in the context of suppression of a number of factors that modulate inflammatory responses. Prostacyclin (PGI 2 ) is the major prostanoid generated in endothelial cells (46) . However, global deletion of the PGI 2 (IP) receptor does not reduce DSS-induced colitis (17) ; suggesting less involvement of PGI 2 and, perhaps, a role for another prostanoid product from endothelial cells, in protection against colitis.
Although we found that COX-2 elimination in both myeloid cells and endothelial cells reduced the proliferative response of epithelial cells in DSS-treated mice, we observed a difference in the apoptotic responses of these two cell-specific Cox-2-knockout mice. At present, this difference remains unexplained. It is possible that this difference is due to minor differences in genetic background resulting from the introduction of the Cre recombinase gene into the Cox-2 floxflox recipients; the phenotype of DSS colitis is affected by genetic background (14) . For this reason, we have used littermate Cre-negative Cox-2 flox/flox mice as controls. Although this makes it difficult to compare quantitative values among groups of mice with different tissue-specific Cox-2 deletions, it seems clear that the role of induced endothelial cell COX-2 expression and its prostanoid products in colitis deserve additional attention. For similar reasons, we have not tried to draw comparisons in the extent of colitis between mice with cell type-specific Cox-2 targeted gene deletions and mice with global systemic Cox-2 gene deletions.
Pharmacological data and studies with global Cox-2-knockout mice demonstrate that COX-2 plays a causal role both in spontaneous human colon cancer and in the most commonly used murine model of spontaneous colon cancer induced in mice by repeated intraperitoneal azoxymethane injection (11, 47) . Similarly, both pharmacological data and Cox-2-knockout studies demonstrate a causal role for COX-2 both in Familial Adenomatous Polyposis (one form of hereditary colon cancer) and its murine analogue (48, 49) . In contrast, studies with Cox-2-knockout mice demonstrate that the murine model of colon cancer most closely associated with inflammation, azoxymethaneinitiated/DSS-promoted colon cancer, does not require COX-2 expression (11) . Thus, the mechanism(s) of tumor promotion for spontaneous and hereditary colon cancers differ(s) from that of colitis-associated colon cancer.
COX-2 protein is constitutively expressed in a variety of human epithelial carcinomas. However, during the beginning of tumor development, COX-2 expression is observed mainly in stromal cells, including fibroblasts, myofibroblasts, endothelial cells and myeloid cells, both in adenomas and in adenocarinomas of human cancers and in murine epithelial cancer models (47) . Conditional deletion of the Cox-2 gene in alternative cell types, using the Cox-2 flox/flox mouse, will provide a means to determine in which of these various stromal cells the COX-2-dependent promotion event(s) in epithelial cancer progression necessary. In particular, cell type-specific COX-2 deletions, using the Cox-2 flox/flox mouse, in spontaneous versus hereditary murine colon cancer models should permit us to determine if the COX-2-driven promotion/progression event is provided by the same cell type, or by different cell types, in these two routes to murine colon cancer. T. Ishikawa et al.
In many human pathologies and murine disease models, induced COX-2 expression is observed in more than one cell type. In this study, we showed a requirement for Cox-2 expression in myeloid and endothelial cells, but not in epithelial cells, for protection against colitis. In a mouse hindlimb model of vascular insufficiency, ischemia-induced revascularization is impaired in mice with a Tie2Cre endothelial cell-specific Cox-2 knockout (50). Similar approaches using Cox-2 conditional knockout mice will be valuable in analyzing the cell-specific roles of COX-2 expression in murine models of inflammatory diseases, neurodegenerative diseases and cancer progression in a variety or organs.
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